Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:31.072Z.
Calculation as of: 2026-10-06T16:57:31.072Z.
Quote observation: 2026-10-06T16:55:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb4a8502ebbb15e11e68a15a33f7d53c7b5c9812bb79594c7d74d11368e8432a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Milestone Pharmaceuticals Inc.
Market Cap
$97.82M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.25M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.54M
EV/EBITDA Ratio
26.08x
TTM Avg
52.21x
3Y Avg
97.08x
5Y Avg
75.85x
Market Cap
$91.25M
EV/EBITDA Ratio
N/A
TTM Avg
51.11x
3Y Avg
51.11x
5Y Avg
51.11x
Market Cap
$104.68M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $97.82M | N/A | N/A | N/A | N/A |
| Korro Bio, Inc. (KRRO)vs › | $97.59M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $97.00M | N/A | N/A | N/A | N/A |
| PolyPid Ltd. (PYPD)vs › | $99.04M | N/A | 57.81x | 57.81x | 8.19x |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.25M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $102.54M | 26.08x | 52.21x | 97.08x | 75.85x |
| Biomea Fusion, Inc. (BMEA)vs › | $91.30M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $91.25M | N/A | 51.11x | 51.11x | 51.11x |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $90.73M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
